This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bermudez, L. E.
Right arrow Articles by Young, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bermudez, L. E.
Right arrow Articles by Young, L. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 03 1996, 546-551, Vol 40, No. 3
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice

LE Bermudez, CB Inderlied, P Kolonoski, M Wu, L Barbara-Burnham and LS Young
California Pacific Medical Center Research Institute, San Francisco 94115, US

Levofloxacin, ofloxacin, and Bay Y 3118 are new fluoroquinolones with variable in vitro bacteriostatic and bactericidal activities against the Mycobacterium avium complex (MAC). The potential therapeutic activities of these agents both alone and combined with ethambutol were evaluated in a human macrophage test system and in the beige mouse animal test system with MAC strain 101. Bay Y 3118 at a human- equivalent dose of 30 mg/kg/day for 4 weeks caused a significant reduction in mortality compared with that in untreated controls (P = 0.02). Bay Y 3118 also caused significant reductions in the number of MAC organisms in the blood, liver tissue, and spleen tissue compared with those in untreated controls. Levofloxacin at a human-equivalent dose of 200 mg/kg/day was associated with a significant reduction in mortality (10 versus 39%); however, treatment with either levofloxacin or ofloxacin (200 mg/kg/day) did not result in significant reductions in the numbers of MAC organisms in blood, liver, and spleen compared with those in untreated controls. When Bay Y 3118 was combined with ethambutol, there was no enhancement in therapeutic activity except in the spleen in terms of CFU per gram (reductions of 89% compared with the untreated control, 63% compared with Bay Y 3118 alone, and 72.5% compared with ethambutol alone). Levofloxacin in combination with ethambutol was more active than either drug alone in the reduction of organisms in blood, liver, and spleen. Bay Y 3118 was the most active fluoroquinolone for monotherapy of MAC infection in beige mice, and the combination of ethambutol plus either levofloxacin or ofloxacin was at least additive. In summary, this study demonstrates that quinolones, although active, are inhibitory against MAC in vivo and that there is little correlation between the activity of quinolones in vitro and the activity in mice.


This article has been cited by other articles:

  • Kohno, Y., Ohno, H., Miyazaki, Y., Higashiyama, Y., Yanagihara, K., Hirakata, Y., Fukushima, K., Kohno, S. (2007). In Vitro and In Vivo Activities of Novel Fluoroquinolones Alone and in Combination with Clarithromycin against Clinically Isolated Mycobacterium avium Complex Strains in Japan. Antimicrob. Agents Chemother. 51: 4071-4076 [Abstract] [Full Text]  
  • Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Wu, M., Aralar, P., Young, L. S. (2001). Telithromycin Is Active against Mycobacterium avium in Mice despite Lacking Significant Activity in Standard In Vitro and Macrophage Assays and Is Associated with Low Frequency of Resistance during Treatment. Antimicrob. Agents Chemother. 45: 2210-2214 [Abstract] [Full Text]  
  • Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., Young, L. S. (2001). Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium avium. Antimicrob. Agents Chemother. 45: 217-222 [Abstract] [Full Text]  
  • Bermudez, L. E., Nash, K., Petrofsky, M., Young, L. S., Inderlied, C. B. (2000). Clarithromycin-Resistant Mycobacterium avium Is Still Susceptible to Treatment with Clarithromycin and Is Virulent in Mice. Antimicrob. Agents Chemother. 44: 2619-2622 [Abstract] [Full Text]  
  • Miltner, E. C., Bermudez, L. E. (2000). Mycobacterium avium Grown in Acanthamoeba castellanii Is Protected from the Effects of Antimicrobials. Antimicrob. Agents Chemother. 44: 1990-1994 [Abstract] [Full Text]  
  • Wu, H.-S., Kolonoski, P., Chang, Y. Y., Bermudez, L. E. (2000). Invasion of the Brain and Chronic Central Nervous System Infection after Systemic Mycobacterium avium Complex Infection in Mice. Infect. Immun. 68: 2979-2984 [Abstract] [Full Text]  
  • den Broek, P. J. v., Koot, T. G. A., Strijen, E. v., Mattie, H. (1999). Intracellular activity of trovafloxacin against Staphylococcus aureus. J Antimicrob Chemother 44: 193-199 [Abstract] [Full Text]  
  • Bermudez, L. E., Kolonoski, P., Wu, M., Aralar, P. A., Inderlied, C. B., Young, L. S. (1999). Mefloquine Is Active In Vitro and In Vivo against Mycobacterium avium Complex. Antimicrob. Agents Chemother. 43: 1870-1874 [Abstract] [Full Text]  
  • Williams, S. L., Harris, N. B., Barletta, R. G. (1999). Development of a Firefly Luciferase-Based Assay for Determining Antimicrobial Susceptibility of Mycobacterium avium subsp. paratuberculosis. J. Clin. Microbiol. 37: 304-309 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»